1. Floyd DN, Langham S, Severac HC, et al. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci 2015;60:299-312.
  2. Bernklev T, Jahnsen J, Schulz T, et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 2005;17:1037-1045.
  3. Clark M, Colombel JF, Feagan BC, et al. American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-339.
  4. D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725-32.
  5. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23; quiz 524.
  6. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83; quiz 464, 484.
  7. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015;12:537-45.
  8. Dulai PS, Sandborn WJ. Next-generation therapeutics for inflammatory bowel disease. Curr Gastroenterol Rep 2016;18:51.
  9. Mocko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis. Pharmacol Rep 2016;68:1237-1243.
  10. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med 2013;368:6-8.
  11. Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut 2012;61:459-65.
  12. Billioud V, Laharie D, Filippi J, et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011;17:152-9.
  13. Carter CT, Leher H, Smith P, et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011;17:385-92.
  14. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114:39-43.
  15. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009;26:936-46.
  16. Bowler GM. Netnography: a method specifically designed to study cultures and communities online. Qual Rep 2010;15:1270-1275.
  17. Perrin A. Social media usage: 2005-2015. Pew Research Center, 2015.
  18. Whitman CB, Reid MW, Arnold C, et al. Balancing opioid-induced gastrointestinal side effects with pain management: Insights from the online community. J Opioid Manag 2015;11:383-91.
  19. Tweet MS, Gulati R, Aase LA, et al. Spontaneous coronary artery dissection: a disease-specific, social networking community-initiated study. Mayo Clin Proc 2011;86:845-50.
  20. Thaker SI, Nowacki AS, Mehta NB, et al. How U.S. hospitals use social media. Ann Intern Med 2011;154:707-8.
  21. Weitzman ER, Adida B, Kelemen S, et al. Sharing data for public health research by members of an international online diabetes social network. PLoS One 2011;6:e19256.
  22. Siegel CA, Levy LC, MacKenzie TA, et al. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1-6.
  23. Cullen G, Donnellan F, Long S, et al. Perceptions of medication safety among patients with inflammatory bowel disease. Scand J Gastroenterol 2010;45:1076-83.
  24. Martinez B, Dailey F, Almario CV, et al. Patient understanding of the risks and benefits of biologic therapies in inflammatory bowel disease: insights from a large-scale analysis of social media platforms. Inflamm Bowel Dis 2017;23:1057-64.
  25. Wong S, Walker JR, Carr R, et al. The information needs and preferences of persons with longstanding inflammatory bowel disease. Can J Gastroenterol 2012;26:525-31.
  26. Promislow S, Walker JR, Taheri M, et al. How well does the Internet answer patients' questions about inflammatory bowel disease? Can J Gastroenterol 2010;24:671-7.
  27. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403-13.
  28. Conjoint analysis (marketing) - Wikipedia. 2017.
  29. Kievit W, van Huist L, van Riel P, et al. Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res (Hoboken) 2010;62:842-7.
  30. Bederman S, Mahomen N, Kreder H, et al. In the eye of the beholder: preferences of patients, family physicians, and surgeons for lumbar spinal surgery. Spine 2010;35:108-15.
  31. Porzsolt F, Clouth J, Deutschmann M, et al. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes 2010;8:125.
  32. Whitman CB, Shreay S, Gitlin M, et al. Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol 2013;8:1942-51.
  33. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769-79.
  34. Lichtenstein GR, Waters HC, Kelly J, et al. Assessing drug treatment preferences of patients with Crohn’s disease. Patient 2010;3:113-123.
  35. Hodgkins P, Swinburn P, Solomon D, et al. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Patient 2012;5:33-44.
  36. Johnson FR, Hauber B, Ozdemir S, et al. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm 2010;16:616-28.
  37. Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal 2009;29:121-36.
  38. Bewtra M, Fairchild AO, Gilroy E, et al. Inflammatory bowel disease patients' willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol 2015;110:1675-81.
  39. Almario C, Keller M, Mosadeghi S, et al. Examining patient decision-making surrounding biologic therapies in inflammatory bowel disease: insights from a conjoint analysis survey. American College of Gastroenterology Annual Meeting. Las Vegas, NV, 2016.